Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C16H15ClO6 |
| Molecular Weight | 338.74 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(OC)C(OC(C)=O)=C2C=C(Cl)C=CC2=C1OC(C)=O
InChI
InChIKey=IFWMVQUGSGWCRP-UHFFFAOYSA-N
InChI=1S/C16H15ClO6/c1-8(18)22-13-11-6-5-10(17)7-12(11)14(23-9(2)19)16(21-4)15(13)20-3/h5-7H,1-4H3
| Molecular Formula | C16H15ClO6 |
| Molecular Weight | 338.74 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Lonapalene (6-chloro-2,3-dimethoxynaphthalene-1,4-diol-diacetate; RS-43179) is a topically effective 5-lipoxygenase inhibitor. Lonapalene was shown to inhibit platelet cyclooxygenase. Lonapalene has been studied in the treatment of psoriasis. Development of lonapalene has been discontinued.
Originator
Approval Year
Sample Use Guides
The pharmacologic and clinical effects of the 5-lipoxygenase inhibitor, lonapalene, have been determined in a double-blind, placebo-controlled, topical study in ten volunteers with psoriasis. A statistically significant clinical improvement was seen in lesions treated with 2% lonapalene ointment as compared with vehicle-treated sites.
Route of Administration:
Transdermal
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:00:54 GMT 2025
by
admin
on
Mon Mar 31 18:00:54 GMT 2025
|
| Record UNII |
WIF31Q54NJ
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
56237
Created by
admin on Mon Mar 31 18:00:55 GMT 2025 , Edited by admin on Mon Mar 31 18:00:55 GMT 2025
|
PRIMARY | |||
|
91431-42-4
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
m802
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | Merck Index | ||
|
C170126
Created by
admin on Mon Mar 31 18:00:55 GMT 2025 , Edited by admin on Mon Mar 31 18:00:55 GMT 2025
|
PRIMARY | |||
|
SUB08568MIG
Created by
admin on Mon Mar 31 18:00:55 GMT 2025 , Edited by admin on Mon Mar 31 18:00:55 GMT 2025
|
PRIMARY | |||
|
5886
Created by
admin on Mon Mar 31 18:00:54 GMT 2025 , Edited by admin on Mon Mar 31 18:00:54 GMT 2025
|
PRIMARY | |||
|
DTXSID00238563
Created by
admin on Mon Mar 31 18:00:55 GMT 2025 , Edited by admin on Mon Mar 31 18:00:55 GMT 2025
|
PRIMARY | |||
|
100000082005
Created by
admin on Mon Mar 31 18:00:55 GMT 2025 , Edited by admin on Mon Mar 31 18:00:55 GMT 2025
|
PRIMARY | |||
|
W-147
Created by
admin on Mon Mar 31 18:00:55 GMT 2025 , Edited by admin on Mon Mar 31 18:00:55 GMT 2025
|
PRIMARY | |||
|
WIF31Q54NJ
Created by
admin on Mon Mar 31 18:00:55 GMT 2025 , Edited by admin on Mon Mar 31 18:00:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL36648
Created by
admin on Mon Mar 31 18:00:55 GMT 2025 , Edited by admin on Mon Mar 31 18:00:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
